According to the USA Today, the FTC wants to ban drug companies from paying to delay generic alternatives.
Agency officials estimate the deals cost American consumers $3.5 billion per year in unnecessarily high drug prices.
The FTC advocates making this ban in the healthcare reform bills being negotiated.
